SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing intense investor frustration as the stock continues a sharp, multi-week decline that has decoupled from broader market gains. The community is actively debating whether this represents an oversold buying opportunity, a structural shift due to mounting AI infrastructure costs and integration concerns, or deliberate algorithmic manipulation.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant attention as retail investors rotate into the stock to gain exposure to high-profile private companies like SpaceX and Anthropic ahead of potential IPOs. Community sentiment is driven by a mix of speculative trading momentum, discussions around the fund's portfolio concentration compared to peers, and anticipation that share scarcity could spark a rapid move toward historical highs.

The Shrimp Army

SHRIMPS is gaining traction as part of a broader trend of aquatic-themed memecoins, with investors debating the potential for rapid gains versus the volatility typical of highly speculative pump-and-dump cycles. The community remains focused on momentum-driven price action and the ability to maintain current levels while comparing the token to other recent market participants in the sector.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is trending following a massive 16% surge driven by a strategic pivot into fabless semiconductor manufacturing and the launch of its AGI CPU, which Wall Street expects to unlock significant high-margin revenue streams. Community sentiment is deeply divided between long-term bulls praising the company's vital role in the AI data center infrastructure and skeptical traders warning that the stock's high valuation is already priced in years ahead.

PRIME is the native token of the Echelon Prime Foundation, a Web3 ecosystem advancing the next generation of gaming. Echelon creates and distributes tools to encourage innovation in, and promote the growth of, novel gaming models and economies. The first game to adopt and utilize PRIME is Parallel, a sci-fi trading card game.

Echelon Prime

Echelon Prime is trending as community members highlight its role as the backbone of on-chain gaming economies, driving speculation about a potential rally fueled by the broader recovery in altcoins. Investors are actively debating accumulation strategies and technical breakouts while looking for signs that the token is poised for a significant move amid the expanding Web3 gaming sector.

BioLLM

BioLLM is currently driving intense social media discourse, with proponents highlighting its focus on AI and bio-computing while skeptics dismiss the asset as a speculative pump-and-dump scheme. The community remains deeply divided, with significant activity focused on aggressive promotion and calls for rapid price movement alongside broader market comparisons.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is facing intense volatility following a highly critical report from Culper Research that alleges the company is engaging in channel stuffing and misleading financial reporting. While the stock has seen a sharp sell-off, the community is deeply divided, with many long-term shareholders dismissing the report as a tactical short-seller attack and urging management to provide a more aggressive, detailed rebuttal to restore market confidence.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant market attention following an 'Outperform' initiation from Mizuho with a $100 price target, fueling speculation about a potential short squeeze. Community sentiment is deeply divided, with bulls pointing to the company's robust proprietary healthcare data moat and institutional backing by ARK Invest, while bears express frustration over price stagnation and recurring selloffs.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron shares are under intense pressure as algorithmic traders react to a Google research announcement regarding an AI memory compression algorithm, while investors continue to weigh the impact of the company's large-scale debt repurchase plan. The community is deeply divided between those viewing the pullback as a buying opportunity given the firm's strong fundamentals and those fearing that recent headline-driven volatility signals a potential cyclical peak.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is currently trending as traders capitalize on a recent surge in CPU demand and price hikes, while simultaneously weighing the stock against broader semiconductor sector volatility and ongoing geopolitical uncertainties. Community sentiment remains split between bullish AI-driven conviction and cautious hedging, with active debate regarding potential gap fills and short-term volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $58.94, denoting a +2.7% move from the preceding trading day.

Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?

Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.

Procyon Advisors LLC Sells 20,349 Shares of Bristol Myers Squibb Company $BMY

Procyon Advisors LLC trimmed its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 56.8% during the fourth quarter, according to the company in its most recent 13F filing with the...

E. Ohman J or Asset Management AB Buys 46,000 Shares of Bristol Myers Squibb Company $BMY

E. Ohman J or Asset Management AB boosted its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 183.2% during the fourth quarter, according to its most recent Form 13F filing with the...

<ul class="summary-bullets"><li>Founder Patrick Soon-Shiong said Abraxane from Bristol Myers Squibb could help boost immune responses when combined with the company’s cancer immunotherapy Anktiva.</li><li>Founder Patrick Soon-Shiong said Abraxane may help “expose” tumors through immune-activating signals and support macrophage activity.</li><li>Anktiva was recently added to Macau’s approved drug list and included by the National Comprehensive Cancer Network for certain bladder cancer patients.</li></ul>Shares of ImmunityBio, Inc. (IBRX)&nbsp;rose over 1% in premarket trading on Tuesday after a newly posted Phase 1 study showed its cancer therapy Anktiva is being tested alongside Bristol Myers Squibb’s Abraxane and other drugs in patients with pancreatic cancer ahead of surgery.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> jumped nearly 11% on Monday, marking its best session in a month.<h2 class="st-heading-2">Phase 1 Trial Tests Anktiva In Pancreatic Cancer</h2>According to a new regulatory update on Monday, the open-label Phase 1 study is evaluating Anktiva in combination with the investigational agents Sotevtamab and Zabadinostat, plus the chemotherapy drugs Gemcitabine and Abraxane, in participants with borderline resectable or locally advanced pancreatic ductal adenocarcinoma.The treatment is being given before surgery, followed by tumor removal and additional immunotherapy afterward, as researchers evaluate the safety and early signals of effectiveness of the combination approach.Participants enrolled in the study will undergo endoscopic ultrasound-guided biopsies of the primary tumor within seven days before treatment begins. Samples will be used for diagnostic evaluation and stored in an approved tissue bank.<h2 class="st-heading-2">Bristol Myers’ Abraxane May Support Anktiva</h2>Soon-Shiong&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2036321510348947567">said on X</a> that Abraxane differs from older chemotherapy agents such as Taxol because it is delivered using albumin, a naturally occurring protein that helps transport the drug across blood vessel walls into the tumor microenvironment.He said the drug enters tumors through a natural transport pathway called GP60 and helps activate macrophages to attack cancer cells while also “exposing” tumors through DAMP signaling, making them easier for natural killer (NK) cells and T cells to recognize and destroy.“So it’s not that we ignore the use of chemo, it’s how we use it to activate the immune system while protecting and activating the lymphocytes with Anktiva,” Soon-Shiong said. Abraxane was originally developed by Abraxis BioScience, which Soon-Shiong founded, and is now marketed by Bristol Myers Squibb for breast, lung and pancreatic cancers.<h2 class="st-heading-2">Anktiva Platform Therapy Strategy Gains Support</h2>The development adds to ImmunityBio’s broader effort to position Anktiva as a platform immunotherapy that works alongside vaccines, checkpoint inhibitors and chemotherapy backbones across multiple cancer types rather than as a standalone treatment.Last week, Soon-Shiong pointed to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-premarket-early-anktiva-immune-data-macau-nod-bull-case/cZ3Xl3sRILc">early immune data</a> from the first 20 participants in an Anktiva study showing increases in absolute lymphocyte counts when the therapy was used with the company’s adenovirus-based cancer vaccine. The trial has enrolled 138 patients randomized to the combination or placebo.He said baseline lymphocyte levels typically decline with age but appeared to increase with Anktiva in the early analysis, supporting the therapy’s immune-stimulating role.<h2 class="st-heading-2">Anktiva Gains Macau Listing, NCCN Backing</h2>Momentum around Anktiva has also been driven by recent regulatory developments, including its addition to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-snap-losing-streak-anktiva-macau-drug-list/cZ3XLBrRIhU">Macau’s approved</a> drug list for bladder cancer. Anktiva now stands alongside therapies from Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Gilead Sciences and Moderna in Macau.&nbsp;In the U.S., the National Comprehensive Cancer Network (NCCN) added Anktiva with BCG as an “other recommended” option for papillary bladder cancer that no longer responds to standard BCG treatment, expanding its positioning beyond carcinoma in situ under treatment guidelines.ImmunityBio has also resubmitted its application seeking to expand Anktiva’s label to papillary bladder cancer after previously receiving a refusal-to-file letter from regulators.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX has slipped to ‘bearish’ levels over the past week from the ‘extremely bullish’ zone amid ‘low’ message volumes over the last 24-hours.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_68b9bc5725.webp" alt="ibrx ss.png" width="973" height="145"><figcaption>IBRX sentiment and message volume as of March 24 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/PureLand/message/648355601">said</a> IBRX shares showed signs of steady accumulation after closing near session highs and, citing recent regulatory and guideline momentum. They expect the stock to climb toward $20 by Friday.<stembedurl>https://stocktwits.com/PureLand/message/648355601</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Dirk1969/message/648354937">said</a> IBRX is “currently the best stock with the most potential.”<stembedurl>https://stocktwits.com/Dirk1969/message/648354937</stembedurl>IBRX stock has surged nearly 250% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Rises Premarket: Anktiva Moves Into Pre-Surgery Pancreatic Cancer Combo Trial With Bristol Myers Drug

The comments come amid the firm’s strategy to position Anktiva as a platform immunotherapy that works along with vaccines, checkpoint inhibitors and chemotherapy.

Equity

Diversified Trust Co. Has $6.82 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Diversified Trust Co. grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 25.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 126,336 shares of the biopharmaceutical company's stock a...

FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma

Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth outlook.

Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?

ImmunityBio bets on Anktiva label expansion to drive growth, but intense Big Pharma competition and premium valuation raise questions about its next phase.

Wealth Enhancement Advisory Services LLC Purchases 318,898 Shares of Bristol Myers Squibb Company $BMY

Wealth Enhancement Advisory Services LLC raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 26.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,533,355 shares of the biopharmaceutica...

Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new clinical trial and real-world data for Camzyos (mavacamten) at the American College of Cardiologys (ACC) Annual Scientific...

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$1.45	--	--	N/A
Q4 '25	$1.23	$1.26	2.79%	BEAT
Q3 '25	$1.51	$1.63	8.00%	BEAT
Q2 '25	$1.07	$1.46	36.87%	BEAT
Q1 '25	$1.49	$1.80	20.43%	BEAT

BMY
Bristol-Myers Squibb Co.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest BMY News

BMYBristol-Myers Squibb Co.